InvestorsHub Logo
Followers 59
Posts 11472
Boards Moderated 0
Alias Born 07/16/2006

Re: alternatepatel post# 17242

Thursday, 05/18/2017 6:46:22 AM

Thursday, May 18, 2017 6:46:22 AM

Post# of 20689

$1.5b is too cheap for the only apparent contender that can potentially achieve interchangeability with Humira (selling $16b/year)



If Momenta had the only apparently interchangeable Humira, let alone a Humira drug that set itself apart, Shire wouldn't have paid to get rid of it and Momenta wouldn't have a $700 mil enterprise value.